CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials

Abstract Menin inhibitors have entered clinical trials for histone lysine methyltransferase 2 A (KMT2A)-rearranged and nucleophosmin 1 (NPM1)-mutant acute leukemias and are demonstrating promising activity. CRISPR base editor screening previously predicted several MEN1 (menin) mutations that have ar...

Description complète

Détails bibliographiques

Auteurs principaux:	Wallace Bourgeois, Hannah E. Rice, Daniela V. Wenge, Florian Perner, Hong Yue, Brandon D. Regalado, George Wan, Jan C. Schroeder, Alba Sommerschield, Charlie Hatton, Shivendra Singh, Sweta Singh, Shipra Bijpuria, Brian M. McKeever, William H. Miller, Jordan F. Safer, Sumaiya Iqbal, Jennifer A. Perry, Eric S. Fischer, John G. Doench, Gerard M. McGeehan, Jevon A. Cutler, Scott A. Armstrong
Format:	Artigo
Langue:	Inglês
Publié:	Nature Portfolio 2026-05-01
Collection:	Nature Communications
Accès en ligne:	https://doi.org/10.1038/s41467-026-72685-1
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!